Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Equal-Weight rating on Beam Therapeutics (NASDAQ:BEAM) but lowered the price target from $41 to $35.
August 09, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Beam Therapeutics but lowered the price target from $41 to $35.
The lowering of the price target by Barclays from $41 to $35 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Beam Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100